Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:MEMNASDAQ:OKYONASDAQ:RENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMEMMatthews Emerging Markets Equity Active ETF$28.98+0.2%$28.90$24.01▼$29.90$57.96M1.0811,384 shs1,521 shsOKYOOKYO Pharma$1.40$1.44$0.92▼$3.25$40.36M0.04155,583 shs49,697 shsRENECartesian Growth Co. II$11.20+0.2%$11.10$10.52▼$11.92$242.14M-0.0157,465 shs244 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMEMMatthews Emerging Markets Equity Active ETF+1.12%+1.69%-0.58%+5.80%+8.24%OKYOOKYO Pharma+5.15%0.00%-6.84%-10.34%+4.38%RENECartesian Growth Co. II+0.18%+0.27%+0.90%+1.63%+6.46%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMEMMatthews Emerging Markets Equity Active ETFN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma1.6766 of 5 stars3.53.00.00.00.61.70.6RENECartesian Growth Co. IIN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMEMMatthews Emerging Markets Equity Active ETF0.00N/A$32.0410.56% UpsideOKYOOKYO Pharma3.00Buy$7.00400.00% UpsideRENECartesian Growth Co. IIN/AN/AN/AN/ACurrent Analyst RatingsLatest RENE, MEM, ZLD, DDDD, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMEMMatthews Emerging Markets Equity Active ETFN/AN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/ARENECartesian Growth Co. IIN/AN/A$0.40 per share28.09($0.64) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMEMMatthews Emerging Markets Equity Active ETFN/AN/A15.28∞N/AN/AN/AN/AN/AOKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/A8/20/2024 (Estimated)RENECartesian Growth Co. II$11.44MN/A0.00∞N/AN/A-65.59%5.02%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMEMMatthews Emerging Markets Equity Active ETF$0.140.48%N/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMEMMatthews Emerging Markets Equity Active ETFN/AN/AN/AOKYOOKYO PharmaN/AN/AN/ARENECartesian Growth Co. IIN/A0.220.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMEMMatthews Emerging Markets Equity Active ETFN/AOKYOOKYO Pharma2.97%RENECartesian Growth Co. II58.96%Insider OwnershipCompanyInsider OwnershipMEMMatthews Emerging Markets Equity Active ETFN/AOKYOOKYO Pharma40.46%RENECartesian Growth Co. II20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMEMMatthews Emerging Markets Equity Active ETFN/A2.00 millionN/ANot OptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionableRENECartesian Growth Co. IIN/A21.62 million17.30 millionNot OptionableRENE, MEM, ZLD, DDDD, and OKYO HeadlinesSourceHeadlineWolverine Asset Management LLC Acquires 104,768 Shares of Cartesian Growth Co. II (NASDAQ:RENE)marketbeat.com - April 23 at 8:48 PMCartesian Growth Co. II (NASDAQ:RENE) Shares Up 0%americanbankingnews.com - April 19 at 2:58 AMCartesian Growth Co. II (NASDAQ:RENE) Short Interest Updatemarketbeat.com - March 28 at 8:23 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioThe Most Bought AI Stock by Congress Isn’t NVIDIAMarch 27, 2024 7:00 AMView The Most Bought AI Stock by Congress Isn’t NVIDIAMicron Technology Results Proves AI is Driving Storage DemandMarch 26, 2024 7:35 AMView Micron Technology Results Proves AI is Driving Storage Demand3 Magnificent Seven Stocks Outperforming the RestApril 19, 2024 8:48 AMView 3 Magnificent Seven Stocks Outperforming the RestGameStop Stock Downtrend Is Intact: The End Game Draws NearMarch 27, 2024 8:47 AMView GameStop Stock Downtrend Is Intact: The End Game Draws NearAll Headlines Company DescriptionsMatthews Emerging Markets Equity Active ETFNYSEARCA:MEMThe Matthews Emerging Markets Equity Active ETF (MEM) is an exchange-traded fund that mostly invests in total market equity. The fund is actively managed to invest in emerging market companies with perceived sustainable growth potential. MEM was launched on Jul 13, 2022 and is managed by Matthews.OKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Cartesian Growth Co. IINASDAQ:RENECartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
